{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:24:33Z","timestamp":1786973073387,"version":"build-2736575974"},"reference-count":21,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MK-3207 was withdrawn from development because of drug-induced liver injury. Metabolic studies identified bioactivation to a protein-reactive 3,5-difluorophenylglyoxal (DFPG) intermediate. Although phenylglyoxal metabolites readily form protein adducts, their immunogenic potential has been poorly understood. We compared the immunogenicity of three DFPG isomers (3,5-, 2,4-, and 3,4-DFPG) using T-cell clones generated from treated healthy donor PBMCs. Reactive clones were detected against isomers with 3,5-DFPG inducing the strongest responses. Activation required antigen processing, and no cross-reactivity with MK-3207 was observed. These findings demonstrate the immunogenicity of 3,5-DFPG and show that structural differences among phenylglyoxal isomers influence T cell activation.<\/jats:p>","DOI":"10.1021\/acs.chemrestox.6c00294","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:02:25Z","timestamp":1785852145000},"page":"1503-1507","source":"Crossref","is-referenced-by-count":0,"title":["In-Vitro\nGeneration of T-Cell Clones to Difluorophenylglyoxal:\nImplications for Understanding the Immunogenicity of MK-3207"],"prefix":"10.1021","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5431-0459","authenticated-orcid":true,"given":"Paul","family":"Thomson","sequence":"first","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L693GE"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gibson","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L693GE"]},{"name":"Murdoch University , , ,","place":["Murdoch, WA, Australia, 6150"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0661-528X","authenticated-orcid":true,"given":"Jackie","family":"Shang","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Nonclinical Drug Safety , Merck & Co. , , ,","place":["West Point, Pennsylvania, United States, 19486"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-2075","authenticated-orcid":true,"given":"Xiaoli","family":"Meng","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L693GE"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Saville","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L693GE"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-4233","authenticated-orcid":true,"given":"Sophie","family":"Grice","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L693GE"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Ford","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L693GE"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3149-3082","authenticated-orcid":true,"given":"Yu","family":"Feng","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Nonclinical Drug Safety , Merck & Co. , , ,","place":["West Point, Pennsylvania, United States, 19486"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Pearson","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Nonclinical Drug Safety , Merck & Co. , , ,","place":["West Point, Pennsylvania, United States, 19486"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oropallo","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Nonclinical Drug Safety , Merck & Co. , , ,","place":["West Point, Pennsylvania, United States, 19486"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Nonclinical Drug Safety , Merck & Co. , , ,","place":["West Point, Pennsylvania, United States, 19486"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Monroe","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Nonclinical Drug Safety , Merck & Co. , , ,","place":["West Point, Pennsylvania, United States, 19486"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4107-7832","authenticated-orcid":true,"given":"Dean","family":"Naisbitt","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L693GE"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"1","key":"2026081708272583000_cit1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/toxsci\/kfaa093","article-title":"Mechanistic Investigations Support\nLiver Safety of Ubrogepant","volume":"177","author":"Smith","year":"2020","journal-title":"Toxicol. Sci."},{"issue":"2","key":"2026081708272583000_cit2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2009.10.031","article-title":"Stimulation of human T cells with\nsulfonamides and sulfonamide metabolites","volume":"125","author":"Castrejon","year":"2010","journal-title":"Journal\nof Allergy and Clinical Immunology"},{"issue":"3","key":"2026081708272583000_cit3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1124\/jpet.111.190900","article-title":"Characterization\nof the antigen specificity of T-cell\nclones from piperacillin-hypersensitive patients with cystic fibrosis","volume":"341","author":"El-Ghaiesh","year":"2012","journal-title":"J. Pharmacol Exp Ther"},{"issue":"6","key":"2026081708272583000_cit4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jaci.2010.12.1119","article-title":"Enhanced antigenicity leads to altered immunogenicity\nin sulfamethoxazole-hypersensitive patients with cystic fibrosis","volume":"127","author":"Elsheikh","year":"2011","journal-title":"J. Allergy Clin Immunol"},{"issue":"5","key":"2026081708272583000_cit5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis:\neffector cells\nare drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J. Allergy\nClin Immunol"},{"issue":"2","key":"2026081708272583000_cit6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tox.2004.12.014","article-title":"Direct\nT-cell stimulations by drugs--bypassing the innate immune system","volume":"209","author":"Pichler","year":"2005","journal-title":"Toxicology"},{"issue":"12","key":"2026081708272583000_cit7","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.4049\/jimmunol.164.12.6647","article-title":"Recognition of sulfamethoxazole\nand its reactive metabolites by drug-specific CD4+ T cells from allergic\nindividuals","volume":"164","author":"Schnyder","year":"2000","journal-title":"J. Immunol"},{"issue":"1","key":"2026081708272583000_cit8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1172\/JCI119505","article-title":"Direct,\nMHC-dependent presentation of the drug sulfamethoxazole to human alphabeta\nT cell clones","volume":"100","author":"Schnyder","year":"1997","journal-title":"J. Clin. Invest."},{"issue":"1","key":"2026081708272583000_cit9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4049\/jimmunol.1100647","article-title":"Mass Spectrometric\nCharacterization\nof Circulating and Functional Antigens Derived from Piperacillin in\nPatients with Cystic Fibrosis","volume":"187","author":"Whitaker","year":"2011","journal-title":"J. Immunol."},{"issue":"4","key":"2026081708272583000_cit10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jaci.2006.12.617","article-title":"Generation\nand characterization of antigen-specific CD4+, CD8+, and CD4+CD8+\nT-cell clones from patients with carbamazepine hypersensitivity","volume":"119","author":"Wu","year":"2007","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"2026081708272583000_cit11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jaci.2006.03.005","article-title":"Activation of T cells by carbamazepine and carbamazepine\nmetabolites","volume":"118","author":"Wu","year":"2006","journal-title":"J. Allergy Clin Immunol"},{"key":"2026081708272583000_cit12","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/all.14652","article-title":"Drug-specific T-cell responses in patients with liver\ninjury following treatment with the BACE inhibitor atabecestat","volume":"76","author":"Thomson","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"2026081708272583000_cit13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/all.15830","article-title":"Patients with naproxen-induced liver injury\ndisplay T-cell memory responses toward an oxidative (S)-O-desmethyl\nnaproxen metabolite but not the acyl glucuronide","volume":"79","author":"Thomson","year":"2024","journal-title":"Allergy"},{"issue":"9","key":"2026081708272583000_cit14","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1111\/j.1600-6143.2009.02788.x","article-title":"Fulminant Liver Failure After Vancomycin in a Sulfasalazine-Induced\nDRESS Syndrome: Fatal Recurrence After Liver Transplantation","volume":"9","author":"Mennicke","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"23","key":"2026081708272583000_cit15","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1016\/S0021-9258(18)94475-3","article-title":"The Reaction\nof Phenylglyoxal with Arginine Residues in Proteins","volume":"243","author":"Takahashi","year":"1968","journal-title":"J. Biol. Chem."},{"key":"2026081708272583000_elcit1403704789","unstructured":"Thomson, P\n          .  Propensity of DFPG\nanalogues to modify human serum proteins and its associated antigenicity.\nUnpublished work."},{"issue":"2","key":"2026081708272583000_cit16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/toxsci\/kfw218","article-title":"From the\nCover: Characterization of Isoniazid-Specific\nT-Cell Clones in Patients with anti-Tuberculosis Drug-Related Liver\nand Skin Injury","volume":"155","author":"Usui","year":"2017","journal-title":"Toxicol. Sci."},{"issue":"2","key":"2026081708272583000_cit17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.4049\/jimmunol.133.2.754","article-title":"Measles virus-specific T4+ human cytotoxic T cell clones\nare restricted by class II HLA antigens","volume":"133","author":"Jacobson","year":"1984","journal-title":"J.\nImmunol."},{"issue":"3","key":"2026081708272583000_cit18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1084\/jem.172.3.779","article-title":"Cytotoxic T cell recognition\nof an\nendogenous class I HLA peptide presented by a class II HLA molecule","volume":"172","author":"Chen","year":"1990","journal-title":"J. Exp Med."},{"issue":"1","key":"2026081708272583000_cit19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1155\/2002\/864789","article-title":"Safety of fluoroquinolones: An update","volume":"13","author":"Mandell","year":"2002","journal-title":"Can. J. Infect Dis"},{"key":"2026081708272583000_cit20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/jac\/dkg209","article-title":"Adverse drug\nreactions: implications for the development of fluoroquinolones","volume":"51","author":"Ball","year":"2003","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Chemical Research in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.chemrestox.6c00294","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/crtoec\/article-pdf\/39\/8\/1503\/66345339\/acs.chemrestox.6c00294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/crtoec\/article-pdf\/39\/8\/1503\/66345339\/acs.chemrestox.6c00294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:27:34Z","timestamp":1786969654000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/crtoec\/article\/39\/8\/1503\/5237562\/In-Vitro-Generation-of-T-Cell-Clones-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,30]]},"published-print":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.chemrestox.6c00294","relation":{},"ISSN":["0893-228X","1520-5010"],"issn-type":[{"value":"0893-228X","type":"print"},{"value":"1520-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}